Skip to main
NEUP
NEUP logo

NEUP Stock Forecast & Price Target

NEUP Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Neuphoria Therapeutics Inc is advancing its drug candidate BNC 210, which has shown significant efficacy in treating social anxiety disorder and post-traumatic stress disorder, as evidenced by positive Phase 2b trial results. Specifically, the trial demonstrated a statistically significant reduction in CAPS-5 total symptom severity at Week 12 and notable improvements in depressive symptoms and sleep quality. Additionally, BNC 210's strong safety profile is supported by extensive patient exposure, with over 1,500 exposures and a considerable number of patients treated beyond 6 and 12 months, reinforcing the company’s prospects in addressing high unmet medical needs in neuropsychiatric disorders.

Bears say

Neuphoria Therapeutics Inc faces a challenging financial outlook primarily due to the potential for failed or inconclusive clinical trials, which can significantly impact the company's ability to secure necessary funding for drug development. The company’s recent valuation has been adversely affected by a low float, raising the risks associated with its market performance. Additionally, ongoing issues with another drug candidate, Lynx1, contribute to this uncertainty, further questioning the prospects for commercial success in addressing the needs of individuals with neuropsychiatric disorders.

NEUP has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Neuphoria Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Neuphoria Therapeutics Inc (NEUP) Forecast

Analysts have given NEUP a Strong Buy based on their latest research and market trends.

According to 2 analysts, NEUP has a Strong Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Neuphoria Therapeutics Inc (NEUP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.